Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Hefei Tianmai Biotechnology Development","sponsor":"Oramed Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Peptide","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Hefei Tianmai Biotechnology Development

    Menu

    Hefei Tianmai Biotechnology Development

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Hefei Tianmai Biotechnology Development

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in Chi...

              Details:

              ORMD-0801 (oral insulin) capsule, with enhanced patient compliance, is currently undergoing phase III clinical trials for the T2DM indication. Drug has the potential to delay the disease progression or even eliminating late-stage complications.

              Lead Product(s): Insulin

              Therapeutic Area: Endocrinology Product Name: ORMD-0801

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Oramed Pharmaceuticals

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 15, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY